Go to content Go to the menu Go to the search

Public Interest Group, Cancérôpôle Ile-de-France

Quick access, personalized services

Search

Advanced search

Cancéropôle Ile-de-France (public interest group)

By discovering radioactivity in 1898, our illustrious patrons, Pierre and Marie Curie, opened the way for cancer treatments with the emergence, some time later, of radiotherapy.  Today, this fundamental progress in the history of therapy continues to inspire the scientific community of UPMC.  This is why, as a contributor to society, UPMC intends participating in the international mobilisation in the fight against cancer by deploying and sharing its innovative research.  And because UPMC is signing up, it is anxious to work closely with those that also consider public health a requirement and a duty.

Created in 2007 the public interest group, Cancérôpôle Ile-de-France, meets this desire to share knowledge and aims to pool the skills, technical resources and existing teams within the seven founding institutions: Assistance Publique-Hôpitaux de Paris, Institut Curie, Institut Gustave Roussy, Institut universitaire d’hématologie, Université Pierre et Marie Curie, Université Paris Diderot, Centre René Huguenin and Institut Pasteur.


These establishments, world-renowned in the field of oncology, such as the Institut Curie and the Institut Gustave Roussy, give the public interest group high visibility in the European and international cancer research arena.

By thus achieving a critical size, this superstructure aims to contribute toward therapeutic innovations and to structure research and its economic development in the Ile-de-France region with regard to the various regional players: research organisations and higher education establishments (such as the CEA (Commissariat à l'Énergie Atomique; French atomic energy commission), CNRS (Centre National de la Recherche Scientifique; French national centre for scientific research), ESPCI (École Supérieure de Physique et de Chimie Industrielles), INSERM (Institut national de la santé et de la recherche médicale; French national institute for health and medical research)), regional authorities, associations and institutions working in the fight against cancer, health industrialists, etc.


Many partnerships have also been initiated with some fifty companies for research programmes particularly in the fields of biotechnology, instrumentation and pharmacy, giving the public interest group a key role in the social and economic fabric of the Ile-de-France region.  Some of these are part of the international competitive cluster, Medicen Paris Region.


Seven key areas of research, covering all innovative research and treatment methods in the field of oncology have been defined by the public interest group for the next three years, including a 'host/tumour relationship' led by Patrice Debré, professor at UPMC in the joint research unit UMRS 543 Cellular and tissue immunology.

> For more information: CancéropôleNouvelle fenêtre website

Nouvelle fenêtre



02/10/08